Caris expands its extensive network of leading
cancer institutions committed to improving patient outcomes through
innovations in precision medicine by welcoming Mass General Cancer
Center
IRVING,
Texas, June 27, 2024 /PRNewswire/ -- Caris
Life Sciences®(Caris), the leading next-generation AI
TechBio company and precision medicine pioneer that is actively
developing and delivering innovative solutions to revolutionize
healthcare and improve the human condition, announced today that
Mass General Cancer Center has joined the Caris Precision
Oncology Alliance™ (POA).
Mass General Cancer Center, a member of Mass General Brigham, is
an integral part of one of the world's most distinguished academic
medical centers and is consistently ranked by U.S. News & World
Report as one of the top cancer centers in the country. Their
commitment to advancing patient care and research has earned Mass
General Cancer Center the recognition as a National Cancer
Institute Comprehensive Cancer Center, one of only 53 centers to
receive this designation.
The Caris POA is a growing network of leading cancer centers and
research consortia across the globe that collaborate to advance
precision oncology and biomarker-driven research, with its members
working together to establish and optimize standards of care for
molecular testing through innovative research to improve clinical
outcomes for cancer patients. POA members are uniquely positioned
to leverage Caris' highly sophisticated AI bioinformatics and
machine learning capabilities across the company's massive
multi-modal database to enable innovative research to improve
clinical outcomes for cancer patients.
"We are thrilled to welcome Mass General Cancer Center, one of
the world's most respected centers, to the Caris Precision Oncology
Alliance," said George W. Sledge,
Jr., MD, EVP and Chief Medical Officer of Caris. "We're
eager to work with their researchers and investigators on our
shared mission of improving outcomes of all patients affected by
cancer through precision oncology research."
The Caris POA includes 92 cancer centers, academic institutions,
research consortia and healthcare systems. These institutions have
early access to the extensive database and artificial intelligence
platform within Caris to establish evidence-based standards for
cancer profiling and molecular testing in oncology. By leveraging
the comprehensive genomic, transcriptomic and proteomic profiling
available through Caris molecular profiling, Caris seeks to provide
this network with the ability to prioritize therapeutic options and
determine which clinical trial opportunities may benefit their
patients. POA members are also able to integrate with a growing
portfolio of biomarker-directed trials sponsored by biopharma.
Additionally, POA member institutions have access to the most
comprehensive multi-modal database in the industry, which includes
matched molecular and clinical outcomes data from hundreds of
thousands of cancer patients, covering over 1 million data points
per patient.
About Caris Life Sciences
Caris Life
Sciences® (Caris) is the leading next-generation AI
TechBio company and precision medicine pioneer that is actively
developing and delivering innovative solutions to revolutionize
healthcare and improve the human condition. Through comprehensive
molecular profiling (Whole Exome and Whole Transcriptome
Sequencing) and the application of advanced AI and machine learning
algorithms, Caris has created the large-scale, multi-modal database
and computing capability needed to analyze and unravel the
molecular complexity of disease. This convergence of sequencing
power, big data and AI technologies provides an unmatched platform
to deliver the next generation of precision medicine tools for
early detection, diagnosis, monitoring, therapy selection and drug
development.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Cambridge (MA),
Tokyo, Japan and Basel, Switzerland. Caris or its distributor
partners provide services in the U.S., Europe, Asia
and other international markets. To learn more, please visit
CarisLifeSciences.com.
Caris Life Sciences Media Contact:
Lisa Burgner
Corpcomm@CarisLS.com
214.294.5606
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-leading-cancer-center-302183876.html
SOURCE Caris Life Sciences